Weinstein Lovell and Winters Pediatric Orthopaedics 7e

367

CHAPTER 11  |  Juvenile Idiopathic Arthritis

113. Silber T, Majd M. Reflex sympathetic dystrophy syndrome in children and adolescents. Report of 18 cases and review of the literature. Am J Dis Child 1988;142:1325. 114. Sherry D, Weisman R. Psychologic aspects of childhood reflex neurovas- cular dystrophy. Pediatrics 1988;81:572. 115. Ladd J, Cassidy J, Martel W. Juvenile ankylosing spondylitis. Arthritis Rheum 1971;14:579. 116. Rahimtoola Z, Finger S, Imrie S. Outcome of total hip arthroplasty in small-proportioned patients. J Arthroplasty 2000;15(1):27. 117. Senac M, Deutsch D, Bernstein B. MR imaging in juvenile rheumatoid arthritis. AJR Am J Roentgenol 1988;150:873. 118. Verbruggen L, Shahabpour M, Roy PV. Magnetic resonance imaging of articular destruction in juvenile rheumatoid arthritis. Arthritis Rheum 1990;33:1426. 119. Yulish B, Lieberman J, Newman A. Juvenile rheumatoid arthritis: assess- ment with MR imaging. Radiology 1987;165:149. 120. Cabral D, Petty R, Fung M. Persistent antinuclear antibodies in children without identifiable inflammatory, rheumatic or autoimmune disease. Pediatrics 1992;89:441. 121. Allen R, Dewez P, Stuart L. Antinuclear antibodies using HEp-2 cells in normal children and in children with common infections. J Paediatr Child Health 1991;27:39. 122. Deane P, Liard G, Siegel D. The outcome of children referred to a pedi- atric rheumatology clinic with a positive antinuclear antibody test but without an autoimmune disease. Pediatrics 1995;95:892. 123. Rosenberg A. Uveitis associated with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1987;16:158. 124. Stillman J, Barry P. Juvenile rheumatoid arthritis: series 2. Arthritis Rheum 1977;20:171. 125. Schaller J. Juvenile rheumatoid arthritis: series 1. Arthritis Rheum 1977; 20:165. 126. Schellekens GA, et al. The diagnostic properties of rheumatoid arthri- tis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43(1):155–163. 127. Kroot EJ, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43(8):1831–1835. 128. van Jaarsveld CH, et al. The prognostic value of the antiperinuclear fac- tor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17(6):689–697. 129. Petty R. HLA-B27 and rheumatic diseases of childhood. J Rheumatol 1990;17:7. 130. Cassidy J, Brody G, Martel W. Monoarticular juvenile rheumatoid arthritis. J Pediatr 1967;70:867. 131. Baldassare A, Chang F, Zuckner J. Markedly raised synovial fluid leu- kocyte counts not associated with infectious arthritis in children. Ann Rheum Dis 1978;37:404. 132. Zuckner J, Baldassare A, Chang F. High synovial fluid leukocyte counts of noninfectious etiology. Arthritis Rheum 1977;20:270. 133. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232. 134. Lindsley C. Uses of nonsteroidal anti-inflammatory drugs in pediatrics. Am J Dis Child 1993;147:229. 135. Mulberg A, Linz C, Bern E. Identification of nonsteroidal antiinflam- matory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr 1993;122:647. 136. Lovell D, Giannini E, Brewer E. Time course of response to nonsteroidal anti-inflammatory drugs in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1984;27:1433. 137. Skeith KJ, Jamali F. Clinical pharmacokinetics of drugs used in juvenile arthritis. Clin Pharmacokinet 1991;21(2):129–149. 138. Giannini E, Cawkwell G. Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Pediatr Clin North Am 1995;42:1099. 139. Huppertz H, Tschammler A, Horwitz A. Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr 1995;127:317.

140. Padeh S, Passwell J. Intraarticular corticosteroid injection in the manage- ment of children with chronic arthritis. Arthritis Rheum 1998;41:1210. 141. Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee mon- arthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008;59(11):1580–1588. 142. Sherry DD, et al. Prevention of leg length discrepancy in young chil- dren with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999;42(11):2330–2334. 143. Giannini EH, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 1992;326(16):1043–1049. 144. Woo P, et al. Randomized, placebo-controlled, crossover trial of low- dose oral methotrexate in children with extended oligoarticular or sys- temic arthritis. Arthritis Rheum 2000;43(8):1849–1857. 145. Ruperto N, et al. A randomized trial of parenteral methotrexate compar- ing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of metho- trexate. Arthritis Rheum 2004;50(7):2191–2201. 146. Wallace CA, Sherry DD. Preliminary report of higher dose metho- trexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19(10):1604–1607. 147. Lovell DJ, et al. Etanercept in children with polyarticular juvenile rheu- matoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342(11):763–769. 148. Lovell D, Giannini E, Reiff A. Long-term efficacy and safety of etaner- cept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended treat- ment trial. Arthritis Rheum 2003;48(1):218. 149. Lovell DJ, et al. Safety and efficacy of up to eight years of continu- ous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58(5):1496–1504. 150. Gerloni V, Lurati A, Gattinara M. Efficacy of infusions of an anti TNF- a antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis. Results of a two years open label prospective study. Arthritis Rheum 2003;48(9):S92. 151. Ardoin S, Rabinovich E, Jaffe G. Infliximab to treat pediatric chronic inflammatory uveitis. Arthritis Rheum 2003;48(9):S93. 152. Burmester GR, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66(6):732–739. 153. Lovell DJ, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359(8):810–820. 154. Foeldvari I, et al. Tumor necrosis factor-alpha blocker in treatment of juve- nile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34(5):1146–1150. 155. Wallis R, Broder M, Wong J. Granulomatous infectious diseases associ- ated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261. 156. Van Rossum MA, Fiselier T, Franssen M. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo- controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41:808. 157. Ansell B, Hall M, Loftus J. A multicenter pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:201. 158. Hertzberger-ten Cate R, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:85. 159. van Rossum MA, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41(5):808–816. 160. Genovese MC, et al. Abatacept for rheumatoid arthritis ­refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11): 1114–1123. 161. Ruperto N, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372(9636):383–391.